Page 3

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.

AstraZeneca scores in lung cancer; Sandoz inks a China deal

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

EyePoint plummets on pivotal data for main drug

Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

Slate, Fulcrum to combine in reverse merger

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

Drug patents protect pharma profits. Track when they’ll expire.

BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

Updated Aug. 4, 2026

Psychedelics developer Definium scores more positive data for LSD pill

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Boulevard starts up with $65M to pursue targeted autoimmune drugs

Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

Trump signs order seeking to upend childhood vaccine schedule

The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Vaderis hauls in $152M to test an AKT-targeting drug

The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

Why Big Pharma is chasing the industry’s most-powerful supercomputer

Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”